Miranda Adams

Miranda S. Adams serves as a Contract Specialist responsible for managing the full lifecycle of complex acquisitions within a federal research and biotechnology-focused organization. She plays a critical role in translating mission needs into legally compliant, performance-based contracts, ensuring alignment with federal acquisition regulations and strategic procurement goals. Her portfolio centers on high-tech R&D and biological manufacturing initiatives, requiring deep technical understanding and rigorous source selection processes. She routinely handles sole-source, competitive sealed bid, and negotiated acquisitions for advanced scientific services and specialized production capabilities, ensuring timely delivery of mission-critical deliverables. Miranda collaborates with a diverse array of contractors, primarily those with specialized expertise in biotechnology research and biological product manufacturing. While no single vendor dominates her award history, she consistently engages firms with proven capabilities in GMP-compliant production, clinical trial support, and translational research services. Her working relationships are characterized by a focus on technical competency, past performance, and regulatory compliance, with an emphasis on fostering long-term partnerships that support sustained innovation and quality assurance. Miranda’s procurement patterns reflect a strong preference for open competition, with 100% of her acquisitions classified as “No Set-Aside.” This indicates a strategic focus on selecting the most technically qualified offerors regardless of socioeconomic status, rather than reserving awards for specific small business categories. While she does not prioritize 8(a), HUBZone, or SDVOSB set-asides, her approach ensures rigorous evaluation based on merit, capability, and value to mission outcomes. Her primary procurement focus lies in NAICS 541714 (Research and Development in Biotechnology), where she acquires contract research, laboratory services, and preclinical development support. She also frequently procures biological product manufacturing under NAICS 325414, including cell-based therapies, recombinant proteins, and other non-diagnostic biologics. Miranda brings specialized expertise in regulatory frameworks governing biologics, including FDA compliance, cGMP standards, and biosafety protocols, making her a key liaison between scientific teams and acquisition professionals.